Up 80% in October, Virgin Galactic Can See a Path Forward
https://www.fool.com/investing/2023/12/22/virgin-galactic-charts-path-to-survival/?source=iedfolrf0000001
Dec 22, 2023 - Could a rising stock price fix Virgin Galactic's biggest problem?
0
Yields Up To 12%: 5 Top Dividend Stocks For December 2023
https://seekingalpha.com/article/4659067-yields-up-to-12-percent-5-top-dividend-stocks-for-december-2023?source=feed
Dec 22, 2023 - We share a widely diversified set of five deeply undervalued dividend stocks that we think will benefit from this shift. Read more here.
0
Snap Up More Shares
https://seekingalpha.com/article/4659101-snap-up-more-shares?source=feed_all_articles
Dec 21, 2023 - Snap Inc. shares doubled in last quarter and have significant upside potential. Snap's goal for 2024 appears achievable. Find out why SNAP stock is a Buy.
0
Tyler (TYL) & NY Police Team Up for Firearm Background Check
https://www.zacks.com/stock/news/2201239/tyler-tyl-ny-police-team-up-for-firearm-background-check?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2201239
Dec 21, 2023 - Tyler (TYL) implements State Firearm Point of Contact Background Check solution for the New York State Police, aligning with the 2022 gun-safety legislation in New York.
0
Adobe (ADBE) Cancels Figma Buyout, Frees Up $6 Billion in Cash
https://www.zacks.com/stock/news/2201205/adobe-adbe-cancels-figma-buyout-frees-up-6-billion-in-cash?cid=CS-ZC-FT-analyst_blog|company_news_tech_sector-2201205
Dec 21, 2023 - Adobe (ADBE) abandons Figma acquisition due to mounting regulatory pressure. This gives the company room for Artificial Intelligence ("AI") innovations and buy backs.
0
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201158
Dec 21, 2023 - Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
0
MillerKnoll (MLKN) Q2 Earnings Beat Estimates, Up Y/Y, View Up
https://www.zacks.com/stock/news/2201132/millerknoll-mlkn-q2-earnings-beat-estimates-up-y-y-view-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2201132
Dec 21, 2023 - MillerKnoll (MLKN) second-quarter fiscal 2024 results benefit from strategic inventory management, improved gross margins and pricing initiatives.
0
Golar LNG (GLNG) Up 4.6% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2201138/golar-lng-glng-up-4-6-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2201138
Dec 21, 2023 - Golar LNG (GLNG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Why Is Jack In The Box (JACK) Up 15.3% Since Last Earnings Report?
https://www.zacks.com/stock/news/2201145/why-is-jack-in-the-box-jack-up-15-3-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2201145
Dec 21, 2023 - Jack In The Box (JACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
https://www.zacks.com/stock/news/2201100/immunovant-imvt-up-on-upbeat-initial-batoclimab-gd-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201100
Dec 21, 2023 - Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.
0